RNA Therapy in Cancer Treatment: From Design to Clinical Translation
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 1064
Special Issue Editor
Interests: melanoma; cancer immunity; cell signal transduction; 3D imaging; plastic surgery
Special Issue Information
Dear Colleagues,
This Special Issue explores the rapidly evolving field of RNA oncology therapy, focusing on innovations in molecular design, delivery platforms, and preclinical-to-clinical translation. We welcome submissions on the development of mRNA vaccines, non-coding RNA modulators (e.g., miRNA, siRNA, circRNA), and innovative strategies to overcome tumor resistance and immune evasion. Topics of interest include the following:
Novel RNA Therapies: mRNA vaccines targeting oncogenes or tumor suppressor genes, RNA interference, and antisense oligonucleotides.
Delivery Systems: Lipid nanoparticles, polymer vectors, and viral vectors optimized for tumor targeting and bioavailability.
Combination Therapy Regimens: Combining RNA therapy with immunotherapy, chemotherapy, or radiotherapy to enhance anti-tumor efficacy.
Clinical Advances: Biomarker-based patient stratification, combination therapy trials, and long-term safety assessments.
We welcome original research, reviews, and perspectives that connect RNA biology with clinical oncology, aiming to accelerate the application of precision RNA therapy in cancer treatment.
Dr. Zhouxiao Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mRNA vaccines
- RNA interference (siRNA/miRNA)
- non-coding RNA therapeutics
- lipid nanoparticles (LNPs)
- tumor microenvironment
- neoantigen targeting
- combination immunotherapy
- clinical translation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
